Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast - Male Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

NCT02333604
View directory record Official record
Conditions
Neoplasms, Cancer, Caregiver
Interventions
Not listed
Lead sponsor
Cancer Support Community, Research and Training Institute, Philadelphia
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 1:29 PM EST
Terminated Phase 1 Interventional

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

NCT06052852
View directory record Official record
Conditions
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
Interventions
BDC-3042, Cemiplimab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 2 Interventional Results available

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

NCT00940225
View directory record Official record
Conditions
Solid Tumors, Cancer
Interventions
Cabozantinib, Placebo
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
34
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 15, 2026, 1:29 PM EST
Completed Not applicable Interventional

Randomized, Controlled Trial With Hybrid Fractional Laser

NCT03647189
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Nov 15, 2026, 1:29 PM EST
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

NCT00499525
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
43
States / cities
Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Nov 15, 2026, 1:29 PM EST
Not listed Phase 2 Interventional

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

NCT00651417
View directory record Official record
Conditions
Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
Interventions
Organic Germanium, Placebo
Dietary Supplement
Lead sponsor
Arizona Oncology Services
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Nov 15, 2026, 1:29 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions
AZD6750, rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 3 Interventional Results available

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

NCT01539317
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Breast Cancer, Menopause
Interventions
Topical liquid lidocaine, Topical saline
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Nov 15, 2026, 1:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 2 Interventional

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

NCT00004157
View directory record Official record
Conditions
Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, recombinant interleukin-11
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

NCT00003107
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Nov 15, 2026, 1:29 PM EST
Terminated Phase 1 Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 15, 2026, 1:29 PM EST
Completed Not applicable Interventional Results available

Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

NCT04902144
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sequim, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 2 Interventional Results available

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

NCT00106002
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Male, Carcinoma, Ductal
Interventions
pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

NCT00436566
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Nov 15, 2026, 1:29 PM EST
Terminated Phase 1 Interventional

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

NCT02576665
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Lymphoma, Sarcoma, Bladder Cancer, Melanoma, IDH1 Mutated Solid Tumors, IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
Interventions
Toca 511, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Denver, Colorado • Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 1 Interventional

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00667641
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Nov 15, 2026, 1:29 PM EST
Active, not recruiting Phase 1 Interventional

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT03845166
View directory record Official record
Conditions
Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions
XL092, Atezolizumab, Avelumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 15, 2026, 1:29 PM EST
Recruiting Phase 2 Interventional

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 1:29 PM EST
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 1 Interventional

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

NCT01245205
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Akt inhibitor MK2206, lapatinib ditosylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Sioux Falls, South Dakota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 2 Interventional

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

NCT00078845
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Nov 15, 2026, 1:29 PM EST
Completed Phase 2 Interventional Results available

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

NCT00054275
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, erlotinib hydrochloride
Drug
Lead sponsor
Paula Silverman, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Nov 15, 2026, 1:29 PM EST
Active, not recruiting Not applicable Interventional

The Genomic Medicine at VA Study

NCT04331535
View directory record Official record
Conditions
Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Polygenic risk score (PRS)
Diagnostic Test
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
50 Years to 70 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 15, 2026, 1:29 PM EST